Japanese Encephalitis Vaccine
Japanese Encephalitis Prevention
ApprovedCommercial
Key Facts
About Sinopharm
Sinopharm is a Fortune Global 500 company and China's largest pharmaceutical conglomerate, encompassing drug distribution, manufacturing, research and development, and healthcare services. The company gained global recognition for developing one of China's first approved COVID-19 vaccines (BBIBP-CorV) and has established itself as a key player in international vaccine diplomacy. With operations spanning across multiple therapeutic areas and a vast distribution network, Sinopharm serves as a critical component of China's healthcare infrastructure.
View full company profile